dexamfetamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anorexics | 841 | 51-64-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 0 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 1 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 40 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 7.40 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 75 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 9, 1955 | FDA | UCB INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anxiety | 79.28 | 15.41 | 116 | 7881 | 217425 | 63263600 |
| Coronary artery dissection | 69.04 | 15.41 | 17 | 7980 | 845 | 63480180 |
| Migraine | 66.11 | 15.41 | 73 | 7924 | 103273 | 63377752 |
| Pre-existing condition improved | 62.05 | 15.41 | 27 | 7970 | 8217 | 63472808 |
| Depression | 60.57 | 15.41 | 97 | 7900 | 196395 | 63284630 |
| Suicidal ideation | 48.63 | 15.41 | 49 | 7948 | 62372 | 63418653 |
| Feeling abnormal | 45.33 | 15.41 | 73 | 7924 | 148319 | 63332706 |
| Cataplexy | 44.48 | 15.41 | 13 | 7984 | 1243 | 63479782 |
| Suspected product quality issue | 37.18 | 15.41 | 8 | 7989 | 217 | 63480808 |
| Product substitution issue | 35.05 | 15.41 | 23 | 7974 | 15973 | 63465052 |
| Sleep apnoea syndrome | 30.59 | 15.41 | 27 | 7970 | 29106 | 63451919 |
| Snoring | 29.15 | 15.41 | 13 | 7984 | 4189 | 63476836 |
| Somnolence | 28.72 | 15.41 | 67 | 7930 | 178618 | 63302407 |
| Therapeutic response unexpected | 27.26 | 15.41 | 21 | 7976 | 18738 | 63462287 |
| Neuroleptic malignant syndrome | 25.60 | 15.41 | 17 | 7980 | 12039 | 63468986 |
| Memory impairment | 23.62 | 15.41 | 45 | 7952 | 104213 | 63376812 |
| Weight decreased | 23.13 | 15.41 | 82 | 7915 | 276716 | 63204309 |
| Disturbance in attention | 22.71 | 15.41 | 26 | 7971 | 38163 | 63442862 |
| Overdose | 20.53 | 15.41 | 45 | 7952 | 115033 | 63365992 |
| Colitis ischaemic | 20.12 | 15.41 | 14 | 7983 | 10694 | 63470331 |
| Product dose omission issue | 18.36 | 15.41 | 68 | 7929 | 234245 | 63246780 |
| Rhabdomyolysis | 18.25 | 15.41 | 25 | 7972 | 43926 | 63437099 |
| Serotonin syndrome | 17.86 | 15.41 | 20 | 7977 | 28662 | 63452363 |
| Contraindicated product administered | 17.82 | 15.41 | 3 | 7994 | 217645 | 63263380 |
| Hypothermia | 17.15 | 15.41 | 14 | 7983 | 13567 | 63467458 |
| Muscle rigidity | 16.98 | 15.41 | 13 | 7984 | 11487 | 63469538 |
| Dermatitis atopic | 16.62 | 15.41 | 12 | 7985 | 9712 | 63471313 |
| Headache | 16.53 | 15.41 | 136 | 7861 | 633105 | 62847920 |
| Bipolar disorder | 16.36 | 15.41 | 11 | 7986 | 7949 | 63473076 |
| Intentional self-injury | 16.14 | 15.41 | 18 | 7979 | 25669 | 63455356 |
| Intentional overdose | 15.56 | 15.41 | 31 | 7966 | 74121 | 63406904 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Oppositional defiant disorder | 112.27 | 24.37 | 23 | 4087 | 526 | 34952295 |
| Decreased eye contact | 108.69 | 24.37 | 22 | 4088 | 473 | 34952348 |
| Aggression | 94.16 | 24.37 | 58 | 4052 | 38906 | 34913915 |
| Bruxism | 90.70 | 24.37 | 24 | 4086 | 1711 | 34951110 |
| Product substitution issue | 81.39 | 24.37 | 34 | 4076 | 10061 | 34942760 |
| Coordination abnormal | 79.77 | 24.37 | 31 | 4079 | 7613 | 34945208 |
| Crying | 76.50 | 24.37 | 28 | 4082 | 5834 | 34946987 |
| Homicidal ideation | 76.04 | 24.37 | 23 | 4087 | 2659 | 34950162 |
| Suicidal ideation | 75.08 | 24.37 | 51 | 4059 | 40337 | 34912484 |
| Anxiety | 65.59 | 24.37 | 69 | 4041 | 99359 | 34853462 |
| Choreoathetosis | 61.78 | 24.37 | 16 | 4094 | 1048 | 34951773 |
| Affect lability | 61.00 | 24.37 | 21 | 4089 | 3662 | 34949159 |
| Poor quality sleep | 57.26 | 24.37 | 25 | 4085 | 8231 | 34944590 |
| Trismus | 56.43 | 24.37 | 18 | 4092 | 2477 | 34950344 |
| Depression | 54.64 | 24.37 | 62 | 4048 | 97036 | 34855785 |
| Irritability | 50.23 | 24.37 | 33 | 4077 | 24657 | 34928164 |
| Mood altered | 49.05 | 24.37 | 23 | 4087 | 8929 | 34943892 |
| Insomnia | 46.39 | 24.37 | 59 | 4051 | 103848 | 34848973 |
| Psychomotor hyperactivity | 44.47 | 24.37 | 22 | 4088 | 9600 | 34943221 |
| Speech disorder | 44.31 | 24.37 | 31 | 4079 | 25655 | 34927166 |
| Posterior reversible encephalopathy syndrome | 43.77 | 24.37 | 22 | 4088 | 9932 | 34942889 |
| Hyperkinesia | 40.99 | 24.37 | 13 | 4097 | 1755 | 34951066 |
| Streptococcal infection | 40.95 | 24.37 | 17 | 4093 | 4944 | 34947877 |
| Depressed mood | 37.30 | 24.37 | 25 | 4085 | 19292 | 34933529 |
| Dyskinesia | 36.22 | 24.37 | 26 | 4084 | 22387 | 34930434 |
| Sleep disorder | 34.31 | 24.37 | 29 | 4081 | 31659 | 34921162 |
| Hypertensive emergency | 34.18 | 24.37 | 10 | 4100 | 1030 | 34951791 |
| Sleep apnoea syndrome | 33.82 | 24.37 | 24 | 4086 | 20297 | 34932524 |
| Dystonia | 33.64 | 24.37 | 19 | 4091 | 10826 | 34941995 |
| Therapeutic response unexpected | 32.74 | 24.37 | 18 | 4092 | 9739 | 34943082 |
| Extrasystoles | 31.21 | 24.37 | 13 | 4097 | 3810 | 34949011 |
| Anger | 29.44 | 24.37 | 18 | 4092 | 11866 | 34940955 |
| Supraventricular extrasystoles | 28.88 | 24.37 | 12 | 4098 | 3496 | 34949325 |
| Drug ineffective | 27.52 | 24.37 | 116 | 3994 | 456635 | 34496186 |
| Tic | 27.47 | 24.37 | 10 | 4100 | 2048 | 34950773 |
| Vision blurred | 26.90 | 24.37 | 30 | 4080 | 45933 | 34906888 |
| Product complaint | 25.83 | 24.37 | 13 | 4097 | 5877 | 34946944 |
| Educational problem | 25.71 | 24.37 | 7 | 4103 | 555 | 34952266 |
| Sexual dysfunction | 25.00 | 24.37 | 13 | 4097 | 6290 | 34946531 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Oppositional defiant disorder | 115.96 | 17.22 | 23 | 8782 | 474 | 79735109 |
| Decreased eye contact | 97.79 | 17.22 | 22 | 8783 | 843 | 79734740 |
| Anxiety | 92.53 | 17.22 | 125 | 8680 | 248387 | 79487196 |
| Product substitution issue | 83.50 | 17.22 | 42 | 8763 | 20214 | 79715369 |
| Aggression | 80.76 | 17.22 | 57 | 8748 | 50901 | 79684682 |
| Bruxism | 80.27 | 17.22 | 26 | 8779 | 4000 | 79731583 |
| Homicidal ideation | 75.80 | 17.22 | 24 | 8781 | 3433 | 79732150 |
| Coronary artery dissection | 71.41 | 17.22 | 18 | 8787 | 1126 | 79734457 |
| Suicidal ideation | 70.31 | 17.22 | 62 | 8743 | 76278 | 79659305 |
| Depression | 70.14 | 17.22 | 102 | 8703 | 216688 | 79518895 |
| Crying | 56.75 | 17.22 | 34 | 8771 | 23009 | 79712574 |
| Coordination abnormal | 54.56 | 17.22 | 30 | 8775 | 17282 | 79718301 |
| Choreoathetosis | 52.09 | 17.22 | 15 | 8790 | 1555 | 79734028 |
| Affect lability | 45.38 | 17.22 | 23 | 8782 | 11236 | 79724347 |
| Overdose | 44.70 | 17.22 | 76 | 8729 | 184130 | 79551453 |
| Feeling abnormal | 44.46 | 17.22 | 70 | 8735 | 159129 | 79576454 |
| Trismus | 43.73 | 17.22 | 18 | 8787 | 5449 | 79730134 |
| Poor quality sleep | 42.09 | 17.22 | 28 | 8777 | 22694 | 79712889 |
| Psychomotor hyperactivity | 41.84 | 17.22 | 25 | 8780 | 16824 | 79718759 |
| Mood altered | 40.51 | 17.22 | 25 | 8780 | 17822 | 79717761 |
| Dyskinesia | 40.47 | 17.22 | 36 | 8769 | 44737 | 79690846 |
| Irritability | 39.03 | 17.22 | 34 | 8771 | 41110 | 79694473 |
| Intentional overdose | 37.36 | 17.22 | 52 | 8753 | 105908 | 79629675 |
| Hyperkinesia | 36.25 | 17.22 | 13 | 8792 | 2716 | 79732867 |
| Speech disorder | 34.50 | 17.22 | 36 | 8769 | 54409 | 79681174 |
| Intentional self-injury | 33.21 | 17.22 | 28 | 8777 | 32391 | 79703192 |
| Streptococcal infection | 32.59 | 17.22 | 17 | 8788 | 8813 | 79726770 |
| Dystonia | 31.73 | 17.22 | 23 | 8782 | 21376 | 79714207 |
| Sleep disorder | 30.13 | 17.22 | 42 | 8763 | 85635 | 79649948 |
| Insomnia | 29.66 | 17.22 | 76 | 8729 | 245094 | 79490489 |
| Posterior reversible encephalopathy syndrome | 29.63 | 17.22 | 24 | 8781 | 26257 | 79709326 |
| Serotonin syndrome | 28.93 | 17.22 | 30 | 8775 | 44997 | 79690586 |
| Educational problem | 28.27 | 17.22 | 7 | 8798 | 407 | 79735176 |
| Tic | 27.92 | 17.22 | 11 | 8794 | 2975 | 79732608 |
| Depressed mood | 27.09 | 17.22 | 30 | 8775 | 48450 | 79687133 |
| Cataplexy | 26.92 | 17.22 | 8 | 8797 | 926 | 79734657 |
| Extrasystoles | 26.57 | 17.22 | 14 | 8791 | 7405 | 79728178 |
| Hypertensive emergency | 25.13 | 17.22 | 10 | 8795 | 2775 | 79732808 |
| Supraventricular extrasystoles | 24.50 | 17.22 | 13 | 8792 | 6974 | 79728609 |
| Therapeutic response unexpected | 24.16 | 17.22 | 19 | 8786 | 19927 | 79715656 |
| Plagiocephaly | 24.01 | 17.22 | 4 | 8801 | 29 | 79735554 |
| Abnormal behaviour | 22.92 | 17.22 | 24 | 8781 | 36397 | 79699186 |
| Nervousness | 22.80 | 17.22 | 23 | 8782 | 33392 | 79702191 |
| Anger | 22.21 | 17.22 | 17 | 8788 | 17145 | 79718438 |
| Shoulder operation | 21.80 | 17.22 | 9 | 8796 | 2743 | 79732840 |
| Neutropenia | 21.74 | 17.22 | 3 | 8802 | 287707 | 79447876 |
| Cardio-respiratory arrest | 21.47 | 17.22 | 41 | 8764 | 108469 | 79627114 |
| Pre-existing condition improved | 21.36 | 17.22 | 11 | 8794 | 5552 | 79730031 |
| Suicide attempt | 21.12 | 17.22 | 35 | 8770 | 82897 | 79652686 |
| Anaemia | 20.30 | 17.22 | 12 | 8793 | 445003 | 79290580 |
| Agitation | 20.13 | 17.22 | 38 | 8767 | 99677 | 79635906 |
| Somnolence | 20.07 | 17.22 | 65 | 8740 | 238916 | 79496667 |
| Disturbance in attention | 19.51 | 17.22 | 26 | 8779 | 50775 | 79684808 |
| Neutrophil hypersegmented morphology present | 19.51 | 17.22 | 3 | 8802 | 12 | 79735571 |
| Colitis ischaemic | 19.40 | 17.22 | 15 | 8790 | 15344 | 79720239 |
| Product quality issue | 18.96 | 17.22 | 21 | 8784 | 33919 | 79701664 |
| Psychiatric decompensation | 18.66 | 17.22 | 9 | 8796 | 3954 | 79731629 |
| Gross motor delay | 18.27 | 17.22 | 4 | 8801 | 135 | 79735448 |
| Pneumonia | 18.22 | 17.22 | 28 | 8777 | 660218 | 79075365 |
| Muscle rigidity | 17.99 | 17.22 | 16 | 8789 | 19866 | 79715717 |
| Fatigue | 17.66 | 17.22 | 168 | 8637 | 929559 | 78806024 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06BA02 | NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics |
| CHEBI has role | CHEBI:35524 | sympathomimetic |
| CHEBI has role | CHEBI:35640 | adrenergic uptake inhibitors |
| CHEBI has role | CHEBI:37962 | adrenergic agents |
| CHEBI has role | CHEBI:48560 | dopaminergic agents |
| CHEBI has role | CHEBI:50910 | agente neurotoxico |
| CHEBI has role | CHEBI:51039 | dopamine reuptake inhibitor |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D000697 | Central Nervous System Stimulants |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018765 | Dopamine Uptake Inhibitors |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
| FDA PE | N0000175729 | Central Nervous System Stimulation |
| FDA EPC | N0000175739 | Central Nervous System Stimulant |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Narcolepsy | indication | 60380001 | DOID:8986 |
| Attention deficit hyperactivity disorder | indication | 406506008 | |
| Gilles de la Tourette's syndrome | contraindication | 5158005 | DOID:11119 |
| Dependent drug abuse | contraindication | 6525002 | |
| Bipolar disorder | contraindication | 13746004 | DOID:3312 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Feeling agitated | contraindication | 24199005 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Chronic heart failure | contraindication | 48447003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Anorexia nervosa | contraindication | 56882008 | DOID:8689 |
| Aggressive behavior | contraindication | 61372001 | |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Cardiomyopathy | contraindication | 85898001 | DOID:0050700 |
| Weight loss | contraindication | 89362005 | |
| Structural disorder of heart | contraindication | 128599005 | |
| Seizure disorder | contraindication | 128613002 | |
| Motor tic disorder | contraindication | 230337001 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Mania | contraindication | 231494001 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Visual impairment | contraindication | 397540003 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Myocardial infarction in recovery phase | contraindication | 418044006 | |
| Hypertensive urgency | contraindication | 443482000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.89 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.5MG;12.5MG;12.5MG;12.5MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 6913768 | May 24, 2023 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| 3.125MG;3.125MG;3.125MG;3.125MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 6913768 | May 24, 2023 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| 6.25MG;6.25MG;6.25MG;6.25MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 6913768 | May 24, 2023 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| 9.375MG;9.375MG;9.375MG;9.375MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 6913768 | May 24, 2023 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| 12.5MG;12.5MG;12.5MG;12.5MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9173857 | May 12, 2026 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| 3.125MG;3.125MG;3.125MG;3.125MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9173857 | May 12, 2026 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| 6.25MG;6.25MG;6.25MG;6.25MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9173857 | May 12, 2026 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| 9.375MG;9.375MG;9.375MG;9.375MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9173857 | May 12, 2026 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| 13.5MG/9HR | XELSTRYM | NOVEN PHARMS INC | N215401 | March 22, 2022 | RX | SYSTEM | TRANSDERMAL | 9456993 | Oct. 24, 2033 | A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE |
| 18MG/9HR | XELSTRYM | NOVEN PHARMS INC | N215401 | March 22, 2022 | RX | SYSTEM | TRANSDERMAL | 9456993 | Oct. 24, 2033 | A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE |
| 4.5MG/9HR | XELSTRYM | NOVEN PHARMS INC | N215401 | March 22, 2022 | RX | SYSTEM | TRANSDERMAL | 9456993 | Oct. 24, 2033 | A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE |
| 9MG/9HR | XELSTRYM | NOVEN PHARMS INC | N215401 | March 22, 2022 | RX | SYSTEM | TRANSDERMAL | 9456993 | Oct. 24, 2033 | A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 12.5MG;12.5MG;12.5MG;12.5MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | March 13, 2023 | PEDIATRIC EXCLUSIVITY |
| 3.125MG;3.125MG;3.125MG;3.125MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | March 13, 2023 | PEDIATRIC EXCLUSIVITY |
| 6.25MG;6.25MG;6.25MG;6.25MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | March 13, 2023 | PEDIATRIC EXCLUSIVITY |
| 9.375MG;9.375MG;9.375MG;9.375MG | MYDAYIS | TAKEDA PHARMS USA | N022063 | June 20, 2017 | RX | CAPSULE, EXTENDED RELEASE | ORAL | March 13, 2023 | PEDIATRIC EXCLUSIVITY |
| 13.5MG/9HR | XELSTRYM | NOVEN PHARMS INC | N215401 | March 22, 2022 | RX | SYSTEM | TRANSDERMAL | March 22, 2025 | NEW PRODUCT |
| 18MG/9HR | XELSTRYM | NOVEN PHARMS INC | N215401 | March 22, 2022 | RX | SYSTEM | TRANSDERMAL | March 22, 2025 | NEW PRODUCT |
| 4.5MG/9HR | XELSTRYM | NOVEN PHARMS INC | N215401 | March 22, 2022 | RX | SYSTEM | TRANSDERMAL | March 22, 2025 | NEW PRODUCT |
| 9MG/9HR | XELSTRYM | NOVEN PHARMS INC | N215401 | March 22, 2022 | RX | SYSTEM | TRANSDERMAL | March 22, 2025 | NEW PRODUCT |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Synaptic vesicular amine transporter | Transporter | INHIBITOR | CHEMBL | CHEMBL | |||||
| Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | Ki | 7 | IUPHAR | CHEMBL | |||
| Sodium-dependent dopamine transporter | Transporter | RELEASING AGENT | Ki | 6.68 | WOMBAT-PK | CHEMBL | |||
| Alpha-1A adrenergic receptor | GPCR | WOMBAT-PK | |||||||
| Cocaine- and amphetamine-regulated transcript protein | Transcription factor | WOMBAT-PK | |||||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 4.84 | CHEMBL | |||||
| Trace amine-associated receptor 1 | GPCR | EC50 | 6.87 | WOMBAT-PK | |||||
| Alpha-2A adrenergic receptor | GPCR | WOMBAT-PK | |||||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.24 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.18 | PDSP | |||||
| Sodium-dependent serotonin transporter | Transporter | EC50 | 5.75 | CHEMBL | |||||
| Sodium-dependent dopamine transporter | Transporter | IC50 | 5.31 | CHEMBL | |||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 4.91 | CHEMBL | |||||
| Trace amine-associated receptor 1 | GPCR | EC50 | 6 | CHEMBL | |||||
| Trace amine-associated receptor 1 | GPCR | EC50 | 7.25 | CHEMBL | |||||
| Trace amine-associated receptor 1 | GPCR | EC50 | 8.70 | CHEMBL | |||||
| Serotonin (5-HT) receptor | GPCR | Kd | 5.35 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019978 | VUID |
| N0000148062 | NUI |
| D02078 | KEGG_DRUG |
| 51-63-8 | SECONDARY_CAS_RN |
| 350708-40-6 | SECONDARY_CAS_RN |
| 221088 | RXNORM |
| 4018004 | VANDF |
| 4018005 | VANDF |
| 4018835 | VANDF |
| 4019978 | VANDF |
| C0011812 | UMLSCUI |
| CHEBI:4469 | CHEBI |
| 1WE | PDB_CHEM_ID |
| CHEMBL612 | ChEMBL_ID |
| CHEMBL3544971 | ChEMBL_ID |
| CHEMBL3989844 | ChEMBL_ID |
| DB01576 | DRUGBANK_ID |
| 2147 | IUPHAR_LIGAND_ID |
| 64770-52-1 | SECONDARY_CAS_RN |
| 5826 | PUBCHEM_CID |
| 1604 | MMSL |
| 40549 | MMSL |
| 4563 | MMSL |
| 4564 | MMSL |
| d00804 | MMSL |
| 001793 | NDDF |
| 001795 | NDDF |
| 006720 | NDDF |
| 387022005 | SNOMEDCT_US |
| 387278002 | SNOMEDCT_US |
| 45207006 | SNOMEDCT_US |
| 50868004 | SNOMEDCT_US |
| D003913 | MESH_DESCRIPTOR_UI |
| CHEMBL1200782 | ChEMBL_ID |
| 1430 | INN_ID |
| TZ47U051FI | UNII |